CervoMed Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John J. Alam
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 20 Park Plaza Boston MA United States of America 02116
- IPO Date
- May 23, 2008
- CIK
- 0001053691
- Website
- cervomed.com
- Similar Companies
- Business
- CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company that develops therapies targeting neuroinflammation and synaptic dysfunction in age-related brain disorders, including dementia with Lewy bodies (DLB), recovery after ischemic stroke, and frontotemporal dementia (FTD). The company focuses on neflamapimod, an investigational, orally administered small-molecule inhibitor of the alpha isoform of p38 mitogen-activated protein kinase (p38MAPKα) that crosses the blood-brain barrier to address reversible aspects of neurodegeneration; it is advancing through late-stage clinical development, including the completed Phase 2b RewinD-LB trial in DLB patients with low Alzheimer's co-pathology, which demonstrated a 64% risk reduction in clinically significant worsening on the Clinical Dementia Rating Sum of Boxes (CDR-SB) scale over 32 weeks (p<0.001) and reductions in plasma glial fibrillary acidic protein (GFAP), alongside Phase 2a trials in stroke recovery and FTD. CervoMed operates primarily in the United States, with plans for global pivotal trials. Founded in 2014 as EIP Pharma Inc. and headquartered in Boston, Massachusetts, the company resulted from a 2023 merger with Diffusion Pharmaceuticals Inc., became publicly traded in August 2023, and completed a $149.4 million private placement financing in April 2024 led by RA Capital Management to fund neflamapimod development through 2025. Recent developments include FDA alignment in November 2025 on Phase 3 trial design for neflamapimod in DLB using CDR-SB as the primary endpoint and plasma ptau181 screening, preparation for global Phase 3 initiation in the second half of 2026, presentation of 32-week RewinD-LB data at the Alzheimer's Association International Conference in July 2025 and CTAD conference in November 2025, additional within-subject RewinD-LB analyses in October 2025 confirming CDR-SB improvements and GFAP correlations, appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer and David Quigley to the board in October 2025, and $27.3 million in cash reserves as of September 30, 2025, supporting operations into Q3 2026.
Company News
CervoMed Shows Progress in Treating Rare Aphasia Condition
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
CervoMed to Participate in September Investor Conferences
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates